Seventh Annual Current Trends in Genitourinary Malignancies
|Event Date/Time: Oct 16, 2010||End Date/Time: Oct 16, 2010|
The Seventh Annual Current Trends in Genitourinary Malignancies regional symposium is designed to provide state-of-the-art information on the clinical management of bladder, kidney, prostate, and testicular cancers. Current evidence-based treatment approaches to all stages of bladder cancer, including surgery, radiation therapy, neoadjuvant therapy, and systemic chemotherapies and targeted therapies, will be discussed with an emphasis on practical clinical context to facilitate integration into practice. The benefits and risks of alternative therapeutic strategies for early-stage renal cell carcinoma will be addressed, along with expert insights on relevant data for the selection of appropriate therapy for individual patients with advanced clear cell and nonâ€“clear cell renal cell carcinoma in multiple settings. A debate will highlight current evidence concerning the management of early-stage testicular cancer using alternative therapeutic approaches. Participants will review recent data on active surveillance, adjuvant therapy, immunotherapy, and emerging systemic therapies for the clinical management of patients with all stages of prostate cancer. In addition, the symposium will include updates on relevant ongoing clinical trials evaluating new therapeutic regimens for the treatment of genitourinary malignancies. This interactive symposium will include didactic sessions, case-based learning, and panel discussions with leading faculty who will offer their opinions regarding the clinical challenges that practicing physicians face today.
The purpose of this activity is to inform participants of the latest advances in the treatment of genitourinary malignancies and to promote their integration into the practice setting as well as to describe future directions in research and clinical trials.
This educational program is directed toward medical, surgical, and radiation oncologists; urologists; internal medicine and primary care physicians; and basic research investigators interested in the treatment and management of patients with kidney, bladder, prostate, and testicular cancers. Fellows, oncology nurses, oncology physician assistants, and pharmacists interested in the treatment of genitourinary malignancies are also invited to attend.
At the conclusion of this symposium, you should be able to:
Compare the clinical value of surgical and ablative therapeutic approaches to early-stage renal cell carcinoma
Incorporate appropriate antiangiogenic therapies, such as multitargeted kinase inhibitors and mTOR inhibitors, into the treatment of advanced renal cell carcinoma based on patient characteristics and prior therapy
Assess the current status of sequential versus combination therapy options for advanced renal cell carcinoma
Apply state-of-the-art management of superficial, invasive, and metastatic bladder cancer, including surgical options and chemotherapy regimens, in the neoadjuvant, adjuvant, and advanced disease settings
Evaluate emerging treatment options, including cytotoxic and targeted agents, for advanced bladder cancer
Discuss the benefits and risks associated with postorchiectomy treatment approaches to early-stage testicular cancer, including observation, chemotherapy, and radiation therapy
Identify and manage appropriate low-risk patients with prostate cancer using active surveillance
Integrate updated concepts for multimodality treatment, including hormonal therapy, chemotherapy, radiation therapy, and surgery, into the management of patients with localized and high-risk prostate cancer
Incorporate immunotherapeutic strategies into the management of patients with advanced prostate cancer
Explain the biologic basis underlying the predisposition of prostate cancer to metastasize to bone and discuss the use of bone-targeted therapeutic agents
Apply appropriate taxane-based chemotherapy to the management of castration-resistant prostate cancer
Evaluate the role of novel cytotoxic and hormonal therapies in the treatment of castration-resistant prostate cancer following progression on standard systemic therapy
Select appropriate patients for enrollment on clinical trials